A 65-year-old man in Mumbai was taking ayurvedic remedies for weeks prior to testing positive for COVID-19. Even when his symptoms worsened and he had trouble breathing, he was reluctant to go to a hospital. He died of COVID-19 in September.
Havaldar said that her uncle followed the advice of a family member who presents videos propagating AYUSH for COVID-19 on Marathi TV channels.
In April, when Charles, the Prince of Wales, recovered from COVID-19, Union minister of state for AYUSH (ayurveda, yoga and naturopathy, unani, siddha and homeopathy), Sripad Naik, claimed that the former had used ayurvedic medicine. The British royal’s office issued a statement refuting the claim.
Yet, the AYUSH ministry in October released recommendations to integrate “Ayurveda and Yoga interventions” into India’s national clinical management protocol for COVID-19. Among other things, it recommends tackling COVID-19 with warm water gargles, applying medicated ghee in nostrils, steam inhalation, drinking “golden milk” (hot milk with turmeric) and kadha/kashayam/kwath (hot infusion with ayurvedic herbs) combined with good diet, sleep and exercise. The clinical protocol recommends patients take ayurvedic formulations such as Ayush-64, Guduchi Ghana Vati, Guduchi with Pipalli and Asvagandha even while suffering from hypoxia (loss of oxygen in the body) and breathlessness due to COVID-19. India had recorded 8.2 million cases and over 122,000 deaths by November 2.
The Ministry of Health and Family Welfare already has a clinical protocol for COVID-19 based on modern medicine and science and the document has been updated multiple times to add or drop new medicines and therapies whenever new evidence has come in. The new AYUSH ministry recommendations -- based on little scientific evidence and some in contradiction with the current clinical protocol -- have lent legitimacy to home remedies and added to confusion over COVID-19.
These AYUSH recommendations have upset some doctors and made frontline workers’ jobs more difficult, we found.
IndiaSpend studied AYUSH ministry’s COVID-19 recommendations and government documents that claim traditional ayurvedic remedies could prevent, manage and treat COVID-19, and noticed serious discrepancies between the protocols for modern and ayurvedic medicine.
One glaring discrepancy between the government’s allopathic and AYUSH protocols was on treating COVID-19 symptoms: The government’s modern medicine clinical management protocol says that moderate COVID-19 symptoms include hypoxia (loss of blood-oxygen) and breathlessness, and such patients should immediately get medical attention and remain at a dedicated COVID-19 centre, not at home. However, the AYUSH protocol suggests that hypoxia and breathlessness pertain to mild COVID-19, and as such, could be treated by consuming herbs mixed in water.
IndiaSpend also studied the 253 citations referenced in the AYUSH recommendations and found deficiencies in the studies cited. For example, the committee cited a 1981 article about a clinical trial for Ayush-64’s efficacy on malaria, which is not available online. AltNews found a copy of this paper, which apparently claimed that patients on AYUSH64 showed an “80% response with the drug”, without specifying what this means.
However, newer research by government agencies found this drug to not be effective against malaria and this was not considered by AYUSH ministry in this recent protocol. This research, for example, published in2000, found that Ayush-64 showed only 50% efficacy compared to chloroquine, after which the researchers discontinued further research.
Many of these studies had not been carried out on humans yet; they were very nascent pre-clinical research involving just mice or chicks. Still others had not even reached the animal testing phase and were merely carried out on computer software. Yet, these studies made definitive conclusions about the usefulness of these herbs to manage COVID-19. The document also repeatedly referred to “trends”, but from incomplete and unpublished studies.
Some citations were from the 1960s, which researchers said was too old to cite as evidence in a clinical protocol for a newly-emerged disease. Several citations had been repeated, many were incomplete and some URLs mentioned opened to pages where no paper had been uploaded. Many of the articles cited were opinion pieces, commentaries and reviews of literature. Some of the articles cited were written by people who were on the same government committee that had recommended the AYUSH treatments, and hence not entirely independent in their assessments.
IndiaSpend emailed questions to the Ministry of AYUSH and also contacted its office-holders by phone about the evidence cited in their protocol. Both the email and phone calls went unanswered. We will update this story when they reply.
Abby Philips, a hepatologist based in Kerala, studied the citations mentioned by the AYUSH ministry and found them lacking in many ways. “There is deception on the part of the AYUSH ministry,” he said.
For example, the AYUSH recommendation had cited references to show the adverse effects, contraindications and limitations of modern medicine for COVID-19 but had not cited any articles to show its positive indications, he said.
A number of the journals in which AYUSH research had been published seem dubious, said Philips. Some, such as the Indian Journal of Pure and Applied Biosciences (IJPAB), had been cited wrongly--in this case as “International Journal of Pure Applied Sciences”. Some journals--such as the International Journal of Pharmacy and Biological Sciences (IJPBS) and the International Journal of Current Microbiology and Applied Sciences (IJCMS)--were not indexed or affiliated to credible databases such as Medline or Scopus, found Philips.
“There is not a single study, cited in the AYUSH ministry document, that was done on human beings to test efficacy of AYUSH drugs on COVID-19,” said Philips.
The new AYUSH protocol had upset India’s largest body of modern medicine doctors, the Indian Medical Association (IMA). In a letter to the government in October, the IMA asked:
Further, the IMA challenged the government and asked it to hand over India’s entire COVID-19 care to the AYUSH ministry if its proposals were truly scientific and effective.
Doctors treating COVID-19 have had the challenges stacked against them right from the beginning (as IndiaSpend reported here and here on staff shortages, lack of equipment and other problems). Apart from the few scientifically proven options available to them, they also have to contend with pseudoscience.
For example, recipes of “Corona Kashayam” circulating on WhatsApp call for boiling water with household ingredients--turmeric, cloves, lemon and ginger--to “cure” COVID-19. A fact check by BoomLive debunked the kashayam cure. State governments in Tamil Nadu and Kerala, for example, officially distributed packets of AYUSH medicines for COVID-19.
Raghuraj Hegde, an ophthalmic plastic surgeon in Bengaluru, was performing surgery in September and the patient suffered excessive and unexplained bleeding. “The patient had done a range of tests before the surgery and there was no reason for him to have had so much bleeding. He was not on any blood thinners either. We couldn’t explain the situation,” said Hegde.
Studies document that commonplace ingredients such as garlic, ginger and turmeric when consumed in certain quantities can affect platelet function and blood coagulation.
“The surgery I performed was an elective surgery and is not generally one where there could be heavy bleeding. So, we did not have blood on stand-by,” said Hegde. Had he known beforehand that the patient was taking herbal remedies that could cause blood-thinning, Hegde said, he would have delayed the surgery and asked the patient to stop the home remedies for a few days first. But this would not be an option in case of emergency surgeries or pregnancies.
Hegde added that his department at Manipal Hospital, Bengaluru, had now asked surgeons to make this a part of pre-surgery protocol.
Ten months into the pandemic, drug after drug promoted as potential treatment for COVID-19 has fallen through. In the last few weeks, major trials have shown that none of the currently prescribed drugs and interventions--remdesivir, lopinavir/ritonavir, hydroxychloroquine, interferon β1, plasma therapy--are successful at treating COVID-19.
And on this very basis, the AYUSH system of medicine has thrown a challenge to modern medicine. In the government’s report, the expert committee that recommended the AYUSH protocol made exactly this argument.
Hydroxychloroquine, tocilizumab, remdesivir, paracetamol, anti-tussives, enoxaparin sodium, heparin, methylprednisolone or dexamethasone and convalescent plasma have all been recommended in the clinical protocol based on “experiences with limited number of subjects mainly for preventing/ managing systemic pathological effects of COVID-19”, they argued. Likewise, the AYUSH Ministry was also recommending four AYUSH medicines--Ayush-64, Guduchi Ghana Vati, Pipalli and Asvagandha--for COVID-19.
“At present, modern medicine does not offer a cure for COVID-19 and its treatment is mostly empirical and symptomatic. Moreover, modern medicine does not offer any specific measure to boost immunity and also has limitations for managing mental health,” argued the expert committee in the document.
In the 10 months of this pandemic, their results have been peer-reviewed and hundreds of papers have been published in journals, becoming take-off points for further research. Clinical trials have also been conducted on humans and some are in advanced phases. And in this process of rigorous testing, many of the initial drug candidates for COVID-19, have, in fact, been junked.
“However, in case of the AYUSH ministry-recommended drugs, the trials were facing difficulties in enrolling volunteers as patients were being courted by several trials at the same time,” said Sanjeev Sharma, director of National Institute of Ayurveda, Rajasthan. “We have not published any new studies on ayurvedic drugs for COVID-19 so far,” he confirmed, adding, “Many studies are being completed and the papers will be published soon.”
(Anoo Bhuyan is a special correspondent at IndiaSpend.)
(The story has been published in arrangement with India Spend. You can read the original story here.)
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)
Published: undefined